Overview of Ocular Melanoma

Overview of Ocular Melanoma

Ocular melanoma is a rare and aggressive eye cancer that primarily affects the pigment-producing cells in the uveal tract, including the iris, ciliary body, and choroid. The condition is considered more complex when it involves large tumors, nearby tissue invasion, or metastasis—most commonly to the liver. Symptoms can include blurred vision, dark spots in the visual field, eye discomfort, or even vision loss in advanced stages.

Management typically involves a multimodal treatment strategy, which may include radiation therapy, surgical excision, or enucleation (removal of the eye) in severe cases. In metastatic disease, systemic therapies like chemotherapy, targeted therapy, or immunotherapy may be needed. Early and accurate diagnosis is essential to maximize treatment options and improve survival outcomes. Routine eye exams and timely intervention are crucial to reduce the risk of severe complications or cancer spread.

Share this infographic with your team—it’s too good to miss 

https://www.delveinsight.com/infographics/ocular-melanoma-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

Epidemiological Segmentation of Ocular Melanoma (7MM, 2020–2034)

The epidemiological breakdown includes:

• Diagnosed incident cases
  
  

• Regional distribution
  
  

• Type-specific analysis
  
  

• Mutation-based segmentation
  
  

• Age-wise categorization
  
  

• Stage-specific cases
  
  

• Total treated cases
  
  

Uveal melanoma accounts for approximately 95% of all ocular melanoma cases, encompassing choroidal, ciliary body, and iris melanomas.
In 2023, 49% of cases in the 7MM were reported in the United States, and around 60% occurred in individuals aged 40–70 years.

See the bigger picture—get the full report

https://www.delveinsight.com/report-store/ocular-melanoma-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

Market Landscape for Ocular Melanoma

The ocular melanoma market in the 7MM was valued at roughly USD 340 million in 2023.

Market Drivers

• Technological advancements in surgery, immunotherapies, and targeted therapies are improving clinical outcomes.
  
  

• Increased awareness is contributing to earlier diagnosis and better treatment uptake, especially in emerging markets.
  
  

• Expanding global healthcare infrastructure supports wider access to modern diagnostics and therapies.
  
  

• Continued R&D investment in novel treatment modalities is fueling innovation and improved patient care.
  
  

Simplified, visualized, and ready for you— see the infographic

Market Challenges

• The rarity of ocular melanoma limits large-scale pharmaceutical investment due to smaller patient populations.
  
  

• High competition and market saturation are creating pricing pressures and reducing margins.
  
  

• Limited public awareness in developing regions delays diagnosis and treatment initiation.
  
  

• Advanced treatments often come with high costs, impacting accessibility and affordability for many patients.
  
  

Emerging Therapies in the Pipeline

Notable investigational drugs for ocular melanoma include:

• BVD-523
  
  

• SD-101
  
  

• IOA-244
  
  

• LNS8801
  
  

• Among others.
  
  

Key Companies in the Ocular Melanoma Space

Leading organizations involved in ocular melanoma drug development include:

• Dana-Farber Cancer Institute / BioMed Valley Discoveries
  
  

• TriSalus Life Sciences
  
  

• iOnctura
  
  

• Linnaeus Therapeutics
  
  

• And others.
  
  

Get the data. Get the insights. Get the report : Click Here